Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + pembrolizumab + finotonlimab + chemotherapy-Ji Dongmei-squamous cell carcinoma of head and neck
- Development stage
- Unknown
- Lead developer
- Ji Dongmei
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination regimen is a multi-agent therapeutic approach being investigated in a Phase III clinical trial (led by investigator Ji Dongmei) for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC). The regimen incorporates cetuximab, a chimeric monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR); a PD-1 inhibitor, which can be either pembrolizumab (a humanized IgG4 monoclonal antibody) or finotonlimab (SCT-I10A, a recombinant humanized IgG4 monoclonal antibody); and a chemotherapy backbone consisting of nab-paclitaxel (albumin-bound paclitaxel) and a platinum agent (cisplatin or carboplatin). By combining EGFR inhibition, immune checkpoint blockade, and cytotoxic chemotherapy, the regimen aims to overcome resistance mechanisms and improve survival outcomes in patients with advanced HNSCC.
- Brand names
- Abraxane
- Other names
- cetuximab + pembrolizumab + finotonlimab + nab-paclitaxel + cisplatincetuximab + pembrolizumab + finotonlimab + nab-paclitaxel + carboplatin
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on cetuximab + pembrolizumab + finotonlimab + chemotherapy-Ji Dongmei-squamous cell carcinoma of head and neck.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + pembrolizumab + finotonlimab + chemotherapy-Ji Dongmei-squamous cell carcinoma of head and neck.